EP4433462A4 - Inhibiteurs de l'usp9x - Google Patents

Inhibiteurs de l'usp9x

Info

Publication number
EP4433462A4
EP4433462A4 EP22896407.8A EP22896407A EP4433462A4 EP 4433462 A4 EP4433462 A4 EP 4433462A4 EP 22896407 A EP22896407 A EP 22896407A EP 4433462 A4 EP4433462 A4 EP 4433462A4
Authority
EP
European Patent Office
Prior art keywords
usp9x
inhibitors
usp9x inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP22896407.8A
Other languages
German (de)
English (en)
Other versions
EP4433462A1 (fr
Inventor
Richard Martinelli
Julian F Bond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prodeg LLC
Original Assignee
Prodeg LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prodeg LLC filed Critical Prodeg LLC
Priority claimed from PCT/US2022/050069 external-priority patent/WO2023091464A1/fr
Publication of EP4433462A1 publication Critical patent/EP4433462A1/fr
Publication of EP4433462A4 publication Critical patent/EP4433462A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP22896407.8A 2021-11-16 2022-11-16 Inhibiteurs de l'usp9x Withdrawn EP4433462A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163279783P 2021-11-16 2021-11-16
PCT/US2022/050069 WO2023091464A1 (fr) 2021-11-16 2022-11-16 Inhibiteurs de l'usp9x

Publications (2)

Publication Number Publication Date
EP4433462A1 EP4433462A1 (fr) 2024-09-25
EP4433462A4 true EP4433462A4 (fr) 2025-07-16

Family

ID=86396480

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22896407.8A Withdrawn EP4433462A4 (fr) 2021-11-16 2022-11-16 Inhibiteurs de l'usp9x

Country Status (3)

Country Link
EP (1) EP4433462A4 (fr)
CA (1) CA3237744A1 (fr)
WO (1) WO2023089601A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119113118B (zh) * 2024-09-19 2025-09-23 中南大学 USP33抑制剂在制备抗SARS-CoV-2病毒药物中的应用、抗病毒药物及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020061261A1 (fr) * 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Inhibition de la peptidase 9x spécifique de l'ubiquitine
WO2020139916A1 (fr) * 2018-12-26 2020-07-02 Forma Therapeutics, Inc. Inhibition de la peptidase 9x spécifique de l'ubiquitine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004224418A1 (en) * 2003-03-21 2004-10-07 Madeleine M. Joullie Tamandarin analogs and fragments thereof and methods of making and using
PT3658148T (pt) * 2017-07-28 2024-08-26 Turning Point Therapeutics Inc Compostos macrocíclicos e utilizações dos mesmos

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020061261A1 (fr) * 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Inhibition de la peptidase 9x spécifique de l'ubiquitine
WO2020139916A1 (fr) * 2018-12-26 2020-07-02 Forma Therapeutics, Inc. Inhibition de la peptidase 9x spécifique de l'ubiquitine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2023091464A1 *

Also Published As

Publication number Publication date
EP4433462A1 (fr) 2024-09-25
WO2023089601A3 (fr) 2023-08-10
WO2023089601A2 (fr) 2023-05-25
CA3237744A1 (fr) 2023-05-25

Similar Documents

Publication Publication Date Title
EP4216951A4 (fr) Inhibiteurs de kras g12d
EP4262803A4 (fr) Inhibiteurs pan-kras de tétrahydropyridopyrimidine
EP4007756C0 (fr) Inhibiteurs de kif18a
EP4472980A4 (fr) Inhibiteurs de pan-kras de quinazoline
EP4007752C0 (fr) Inhibiteurs de kif18a
EP4495113A4 (fr) Inhibiteur de kif18a
EP4007753C0 (fr) Inhibiteurs de kif18a
EP4434979A4 (fr) Inhibiteur de kif18a
EP3980011A4 (fr) Inhibiteurs de sarm1
EP4247372A4 (fr) Inhibiteurs de kallicréine plasmatique
EP4168398A4 (fr) Inhibiteur de tyk -2
EP4003986A4 (fr) Composés inhibiteurs
EP4452967A4 (fr) Inhibiteurs du sars-cov-2
LT4192813T (lt) Transgliutaminazių inhibitoriai
EP4481051A4 (fr) D-allulose-3-épimérase modifiée
EP3976797A4 (fr) Inhibiteurs anti-crispr
EP4226919A4 (fr) Inhibiteur de la ferroptose
EP4210694A4 (fr) Inhibiteurs de la kallicréine plasmatique
DK4192814T3 (da) Transglutaminase-hæmmere
EP4178620A4 (fr) Inhibiteurs de la kallicréine plasmatique
DE112023002022A5 (de) Isomatte
EP4405334C0 (fr) Inhibiteurs de la sortiline
DK4192812T3 (da) Transglutaminase-inhibitorer
EP4448515A4 (fr) Inhibiteurs de plpro
EP4241545C0 (fr) Bineuse universelle

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240604

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20250613

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 273/00 20060101AFI20250606BHEP

Ipc: A61P 29/00 20060101ALI20250606BHEP

Ipc: A61P 35/00 20060101ALI20250606BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

17Q First examination report despatched

Effective date: 20260603

18W Application withdrawn

Effective date: 20260612